Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Estradiol hemihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What is Gina Gina is a vaginal tablet and contains estradiol.
2.
e Gina
Medical history and Pharmacy Reviews
1
Before you start using Gina, your pharmacist will ask about your own and your family's medical history. They may also ask you about your menopause and what symptoms you have had. This is to make sure that Gina is suitable for you and that you do not need to see your doctor before using Gina or for any other treatments that may be more suitable. Once you have started using Gina you should review your treatment regularly with your pharmacist. Let your doctor know that you are using Gina at your next routine appointment. The use of HRT carries some risks, which need to be considered when deciding whether to start using it, or whether to carry on using it. You should go for regular breast and cervical screening as recommended by your doctor. Do not use Gina if any of the following applies to you. If you are not sure about any of the points below, talk to your pharmacist before using Gina. Do not use Gina if:
2
following during treatment:
Uterine fibroids (Leiomyoma); Increased risk of developing blood clots (e.g. you are unable to walk for a long time because of major surgery/injury/illness, you are overweight with a BMI greater than 30 kg/m2, any of your close relatives has ever had a blood clot in the legs or lungs); Increased risk of getting womb, ovarian or breast cancer (e.g. having a close relative who has had any of these cancers); High blood pressure; Liver disorders, such as a benign liver tumour; Diabetes; Gallstones; Migraines or severe headaches; Systemic lupus erythematosus, (SLE); Epilepsy; Asthma; A disease affecting the eardrum and hearing (otosclerosis); A very high level of fat in your blood (triglycerides); Fluid retention due to cardiac or kidney problems; Hereditary and acquired angioedema.
Cancer of the womb lining (endometrial cancer) and excessive thickening of the womb lining (endometrial hyperplasia) Taking oestrogen-only systemic HRT for a long time can increase the risk of developing cancer of the womb lining (the endometrium). It is uncertain whether there is a similar risk with Gina when it is used for repeated or long term (more than one year) treatments. However, Gina has been shown to have very low absorption into the blood, and therefore the addition of a progestogen is not necessary. If you get any vaginal bleeding e.g. breakthrough bleeding or spotting, especially after using the product for some time, it may be nothing to worry about but you should stop using Gina and seek prompt advice from your doctor. It could be a sign that your endometrium has become thicker. General Information – What you should know about HRT Risks associated with HRT
3
Gina is a local vaginal HRT. Other HRT medicines which circulate in the blood and are used to treat hot flushes and other menopausal symptoms are known as systemic HRT. These are known to increase the risk of some conditions occurring, especially when used for a long time. It is thought that the risk of these conditions may not increase by as much with Gina as with systemic HRT, but this is not known for sure: See section 4 for more detail on risk/side effects with systemic HRT.
Gina
Always use this medicine exactly as described in this leaflet or as your pharmacist has told you. Check with your pharmacist if you are not sure. Gina is a tablet for vaginal use only. Each vaginal tablet comes preloaded in a single-use applicator. Using intravaginal applicators can sometimes cause minor injury in your vagina, especially if inserted or removed without care or if your vaginal atrophy (thinning) is severe. Speak to your doctor or pharmacist if you experience any difficulties with using the vaginal applicator, as your doctor may be able to prescribe another vaginal oestrogen preparation that is more suitable for you.
How much to use
4
You can restart using Gina at any time provided the product is still suitable for use (see section 2) and your overall health is unchanged.
Possible side effects
Like all medicines, Gina can cause side effects, although not everybody gets them. Stop using this medicine and seek urgent medical attention if you have a serious allergic reaction to Gina: A serious allergic reaction may occur only very rarely. Signs may include: • Suddenly feeling unwell with sweating; • Vomiting; • Difficulty in breathing; • Rapid heartbeat or feeling dizzy. Stop using Gina and seek prompt advice from your doctor if: •You develop any new vaginal bleeding, spotting or itching.
5
Common: may affect up to 1 in 10 people • Headache; • Stomach pain; • Vaginal bleeding, discharge or discomfort. Uncommon: may affect up to 1 in 100 people • An infection of the genitals caused by a fungus; • Nausea (Feeling sick); • Rash; • Weight increase; • Hot flush; • High blood pressure. Not known (cannot be estimated from the available data)
reported with systemic HRT treatments: HRT medicines which circulate in the blood and used to treat hot flushes and other menopausal symptoms are known as 'systemic HRT'. These medicines include oral tablets and patches (transdermal patches) or gels which go on the skin. Systemic HRT increases the risk of some conditions occurring, especially when used for a long time (see below). Gina contains a low dose of oestrogen which works locally in the vagina. Gina is classed as a local vaginal HRT, not a systemic HRT. It is thought that the risks associated with local HRT's such as Gina are lower than those associated with systemic HRT's, although it is not known for sure.. You should speak with your doctor or pharmacist if you are concerned. Breast cancer Evidence suggests that using Gina does not increase the risk of breast cancer in women who had no breast cancer in the past. It is not known if Gina can be safely used in women who had breast cancer in the past. Check your breasts regularly and see your doctor if you notice any changes such as: • dimpling or soreness of the skin (sometimes looking like an orange peel); • changes in the nipple (such as discharge or the nipple turns inwards);
6
The risk of ovarian cancer varies with age. For example, in women aged 50 to 54 who do not take HRT, about 2 women in 2,000 will be diagnosed with ovarian cancer over a 5-year period. For women who have been taking HRT for 5 years, there are about 3 cases per 2,000 users (i.e. about 1 extra case). Blood clots in a vein (thrombosis) The risk of blood clots in the veins is about 1.3 to 3 times higher in systemic HRT users than in nonusers, especially during the first year of taking it. Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, fainting or even death. You are more likely to get a blood clot in your veins as you get older. Tell your doctor if any of these situations applies to you: • You are unable to walk for a long time because of major surgery, injury or illness (see also section 3, 'If you need to have surgery'). • You are seriously overweight (BMI greater than 30 kg/m2). • You have any blood clotting problem that needs long-term treatment with a medicine used to prevent blood clots. • If any of your close relatives has ever had a blood clot in the leg, lung or another organ. • You have systemic lupus erythematosus (SLE). • You have cancer. Signs of a blood clot to look out for include:
7
For more information about these side effects, see Section 2. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.
Gina
Keep this medicine out of the sight and reach of children. Do not refrigerate. Do not use this medicine after the expiry date which is stated on the carton and blister after 'EXP'. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. This medicine may cause risk to the aquatic environment. 6.
What Gina contains
8
7.
User instructions
Step 1 Wash your hands and get into a comfortable, relaxed position – this could be standing up or lying down.
Step 2
Figure A
Tear off one of the blister packs and open it at the end. Separate the plastic wrapper and remove the applicator (see Figure A). If after opening the plastic wrapper you see that the tablet has come out of the applicator but has not fallen out of the plastic wrapper, carefully put it back into the end of the applicator ready for insertion. Keep your hands clean and dry while handling the tablet.
Step 3
Figure B
Hold the applicator so that the finger of one hand can press the applicator plunger (see Figure B).
Step 4
Figure C
If prior to insertion the tablet falls out of the end of the applicator, throw the tablet and applicator away and start again with a new applicator.
lying down
Insert the applicator carefully into your vagina (either lying down or standing up, see Figures C and D). You should aim to insert about half of the applicator, but only go as far as is comfortable – don't force it. Gently press the applicator plunger until you feel a click, this confirms the tablet has been released. The tablet will then attach itself to the vaginal wall. Don't worry, it won't fall out if
Figure D
9
you stand up or walk.
standing up
Step 5 Gently remove the applicator and dispose of it, along with the plastic wrapper, in the bin.
Remember, Gina should be used once daily for the first 2 weeks (i.e. initial dose). After this, the dose is reduced to just twice a week (i.e. maintenance dose). To help you keep track, below is a chart for the first 2 weeks for the initial dose. There is also space to write your 2 chosen days (e.g. Tuesday and Friday) for the maintenance dose. Initial dose: 1 tablet daily for 2 weeks Week 1
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Week 2 Maintenance dose: 1 tablet twice per week (aim to leave 3-4 days between each dose) My chosen days are:
[
] and [
]
Please see section 3 if you are restarting Gina or switching from another product.
10
Day 7
Gina 10 micrograms vaginal tablets comes as tablet containing 10mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Gina 10 micrograms vaginal tablets is estradiol hemihydrate.
Medicines with the same active substance, strength and form include: Vagifem 10 micrograms vaginal tablets, Vagirux 10 micrograms vaginal tablets, Estradiol 10 mcg Vaginal Tablets. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Gina 10 micrograms vaginal tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women aged 50 years and above, who have not had a period for at least 1 year (see section 5.1).
Gina is administered intravaginally as a local oestrogen therapy by use of an applicator.
Initial dose: One vaginal tablet daily for two weeks.
Maintenance dose: One vaginal tablet twice a week.
Reinstituting treatment: For patients still experiencing symptom relief after a break from therapy, it is recommended that treatment is restarted at the maintenance dose. For patients experiencing bothersome symptoms again after a break from therapy, it is recommended to restart treatment at the initial daily dose regimen for 2 weeks, followed by the maintenance twice weekly dose.
Switching from other local vaginal oestrogen preparations: Patients experiencing symptom relief from vaginal oestrogen preparations that are being used at the recommended dose can be switched to the maintenance dose of Gina provided:
• The woman has used her current vaginal oestrogen product for more than 3 months, and;
• Her symptoms are adequately controlled, and;
• Her health status is unchanged since her last prescription.
Treatment may be started on any convenient day.
If a dose is forgotten, it should be used as soon as the patient remembers. A double dose should be avoided.
For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used.
For oestrogen products for vaginal application of which the systemic exposure to the oestrogen remains within the normal postmenopausal range, such as Gina, it is not recommended to add a progestagen (but see section 4.4, 'Special warnings and precautions for use', 'Endometrial hyperplasia and carcinoma').
Gina may be used in women with or without an intact uterus.
Method of administration:
1. Open the blister pack at the plunger end.
2. Insert the applicator in the vagina until resistance is met (8-10 cm).
3. Release the tablet by pressing the plunger.
4. Withdraw the applicator and discard.
• Known hypersensitivity to the active substance or to any of the excipients
• Known, past or suspected endometrial cancer
• Undiagnosed genital bleeding
• Untreated endometrial hyperplasia
• Women with an intact uterus who have previously been treated with unopposed systemic oestrogens
• Vulval dermatoses
• Current vaginal infection prior to starting treatment
• Vulval rash
• Severe vaginal itching
• Known, past or suspected oestrogen-dependent malignant tumours (e.g breast cancer, ovarian cancer)
• Previous or current venous thromboembolism (deep venous thrombosis, pulmonary embolism)
• Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction, ischaemic stroke)
• Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency, see section 4.4)
• Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal
• Porphyria.
Treatment initiation or reinstitution and medical examination
For the treatment of postmenopausal symptoms, HRT should only be initiated or reinstituted for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at every pharmacy visit for resupply and HRT should only be continued as long as the benefit outweighs the risk.
Before initiating or reinstituting hormone therapy, a complete personal and family medical history should be obtained. Women should be referred to their doctor before or at any time during treatment if this or the contraindications and warnings for use indicate a need for a physical (including pelvic and breast) examination by a doctor. Continued suitability of treatment with Gina should be verified at each supply. Women should be advised to report any unexpected vaginal bleeding to their doctor or nurse. Women should also be advised what changes in their breasts should be reported to their doctor or nurse (see 'Breast cancer' below). Investigations including appropriate imaging tools, e.g. mammography, should be carried out in accordance with currently accepted screening practices, modified to the clinical needs of the individual.
Conditions requiring a doctor referral before treatment initiation
• Women with a history of:
•
Endometriosis (see below) unless:
o
She has previously received a prescripiton for vaginal oestrogens and her health status is unchanged since her last prescription, and
o
she has no recent symptoms of endometriosis ;
•
Endometrial hyperplasia (see below) unless:
o
She has previously received a prescripiton for vaginal oestrogens and her health status is unchanged since her last precription, or
o
She has had a hysterectomy.
Women receiving hormonal therapy, including systemic HRT, unless she has previously received a prescription for a concurrent vaginal oestrogen product and her health status is unchanged since her last prescription.
•
Women switching to Gina from another vaginal oestrogen product who have:
o
Used their current vaginal oestrogen product for less than 3 months, or;
o
Been using their vaginal oestrogen product at the recommended dose and are experiencing bothersome symptoms
Follow-up
Women with symptoms that do not start to improve or worsen after 3 months of treatment, should be referred to their doctor.
The dose of Gina should not be increased.
If Gina does not relieve symptoms adequately, advice from a doctor should be sought.
The intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
Symptoms often recur when the treatment is stopped
Reasons for immediate withdrawal of therapy
Therapy should be discontinued, and advice sought from a doctor in case a contraindication is discovered or if the following situations occur or recur during treatment:
• New onset of vaginal bleeding or spotting
• New onset of vaginal itching
• Vaginal infection not adequately treated by a pharmacy treatment
• Symptoms of endometriosis
Prompt advice should also be sought from a doctor in the following situations:
• Jaundice or deterioration in liver function
• Significant increase in blood pressure
• New onset of migraine-type headache
• Pregnancy
Endometrial hyperplasia and carcinoma
Women with an intact uterus with abnormal bleeding of unknown aetiology or women with an intact uterus who have previously been treated with unopposed oestrogens should be examined with special care in order to exclude hyperstimulation/malignancy of the endometrium. Therefore use of vaginal oestrogens in these women should remain under the supervision of a doctor.
In women with an intact uterus the risk of endometrial hyperplasia and carcinoma is increased when systemic oestrogens are administered alone for prolonged periods. For oestrogen products for vaginal application of which the systemic exposure to oestrogen remains within the normal postmenopausal range, such as Gina, it is not recommended to add a progestagen.
Endometrial safety of long-term (more than one year) or repeated use of local vaginally administered oestrogen is uncertain. Therefore, if repeated, treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.
If bleeding or spotting appears at any time during therapy, the reason should be investigated, which may include endometrial biopsy to exclude endometrial malignancy. The woman should be advised to contact her doctor in case bleeding or spotting occurs during treatment with Gina.
Unopposed oestrogen stimulation may lead to premalignant or malignant transformation in the residual foci of endometriosis. Therefore, caution is advised when using this product in women who have undergone hysterectomy because of endometriosis, especially if they are known to have residual endometriosis.
The following risks have been associated with systemic HRT and apply to a lesser extent for oestrogen products for vaginal application of which the systemic exposure to the oestrogen remains within the normal postmenopausal range.
The pharmacokinetic profile of Gina shows that there is very low systemic absorption of estradiol during treatment. A minor degree of systemic absorption may occur in some patients, especially during the first two weeks of once-daily administration. However, average plasma E2 concentrations (Cave (0-24)) at all evaluated days remained within the normal postmenopausal range in all subjects (see section 5.2).
However, being an HRT product, the following need to be considered, especially for long-term or repeated use of this product.
Conditions that may be aggravated during exposure to oestrogen
The following conditions may recur or be aggravated during oestrogen treatment. If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be advised to inform their doctor that they are using Gina and seek advice from a doctor if they recur or are aggravated during treatment:
• Leiomyoma (uterine fibroids)
• Risk factors for thromboembolic disorders (see below)
• Risk factors for oestrogen-dependent tumours, e.g. 1st degree heredity for breast cancer
• Hypertension
• Liver Disorders (e.g. liver adenoma)
• Diabetes mellitus with or without vascular involvement
• Cholelithiasis
• Migraine or (severe) headache
• Systemic lupus erythematosus
• Epilepsy
• Asthma
• Otosclerosis.
Breast cancer
Epidemiological evidence from a large meta-analysis suggests no increase in risk of breast cancer in women with no history of breast cancer taking low dose vaginally applied oestrogens. It is unknown if low dose vaginal oestrogens stimulate recurrence of breast cancer.
Ovarian cancer
Ovarian cancer is much rarer than breast cancer.
Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only systemic HRT, which becomes apparent within 5 years of use and diminishes over time after stopping.
Venous thromboembolism
Systemic HRT is associated with a 1.3- to 3-fold risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of HRT than later (see section 4.8).
Patients with known thrombophilic states have an increased risk of VTE and HRT may add to this risk. HRT is therefore contraindicated in these patients (see section 4.3).
Generally recognised risk factors for VTE include use of oestrogens, older age, major surgery, prolonged immobilisation, obesity (BMI >30 kg/m2), pregnancy/postpartum period, systemic lupus erythematosus (SLE) and cancer. There is no consensus about the possible role of varicose veins in VTE.
As in all postoperative patients, prophylactic measures need to be considered to prevent VTE following surgery. If prolonged immobilisation is to follow elective surgery, temporarily stopping HRT 4 to 6 weeks earlier is recommended. Treatment should not be restarted until the woman is completely mobilised.
In women with no personal history of VTE but with a first degree relative with a history of thrombosis at a young age, screening may be offered after careful counselling regarding its limitations (only a proportion of thrombophilic defects are identified by screening).
If a thrombophilic defect is identified which segregates with thrombosis in family members or if the defect is 'severe' (e.g. antithrombin, protein S, or protein C deficiencies or a combination of defects), HRT is contraindicated.
Women already on chronic anticoagulant treatment require careful consideration of the benefit-risk of use of HRT.
If VTE develops after initiating therapy, the drug should be discontinued. Patients should be told to contact their doctors immediately when they are aware of a potential thromboembolic symptom (e.g. painful swelling of a leg, sudden pain in the chest, dyspnoea).
Coronary artery disease (CAD)
Randomised controlled data found no increased risk of CAD in hysterectomised women using systemic oestrogen-only therapy.
Ischaemic stroke
Systemic oestrogen-only therapy is associated with an up to 1.5-fold increase in risk of ischaemic stroke. The relative risk does not change with age or time since menopause. However, as the baseline risk of stroke is strongly age-dependent, the overall risk of stroke in women who use HRT increases with age (see section 4.8).
Other conditions
Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully observed.
Women with pre-existing hypertriglyceridaemia should be followed closely during oestrogen replacement or hormone replacement therapy, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.
Exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema.
Oestrogens increase thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone (as measured by protein-bound iodine (PBI)), T4 levels (by column or by radioimmunoassay) or T3 levels (by radioimmunoassay). T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Other binding proteins may be elevated in serum, i.e. corticoid binding globulin (CBG), sex-hormone-binding globulin (SHBG) leading to increased circulating corticosteroids and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
The minimal systemic absorption of estradiol with local vaginal administration (see section 5.2 'Pharmacokinetic Properties') is likely to result in less pronounced effects on plasma binding proteins than with systemic hormones.
HRT does not improve cognitive function. There is some evidence from the WHI trial of increased risk of probable dementia in women who start using continuous combined or oestrogen-only HRT after the age of 65.
Evidence regarding the risks associated with HRT in the treatment of premature menopause is limited. Due to the low level of absolute risk in younger women, however, the balance of benefits and risks for these women may be more favourable than in older women.
Due to the vaginal administration and minimal systemic absorption, it is unlikely that any clinically relevant drug interactions will occur with Gina. However, interactions with other locally applied vaginal treatments should be considered.
Gina is not indicated during pregnancy. If pregnancy occurs during medication with Gina, treatment should be withdrawn immediately. The results of most epidemiological studies to date relevant to inadvertent foetal exposure to oestrogens indicate no teratogenic or foetotoxic effects.
Lactation
Gina is not indicated during lactation.
No effects known.
Adverse events from clinical trials:
More than 673 patients have been treated with estradiol 10 micrograms vaginal tablets in clinical trials, including over 497 patients treated up to 52 weeks.
Oestrogen-related adverse events such as breast pain, peripheral oedema and postmenopausal bleedings have been reported with estradiol 10 micrograms vaginal tablets at very low rates, similar to placebo, but if they occur, they are most likely present only at the beginning of the treatment. The adverse events observed with a higher frequency in patients treated with estradiol 10 micrograms vaginal tablets as compared to placebo and which are possibly related to treatment are presented below.
System organ class
Common≥1/100 to <1/10
Uncommon≥1/1,000 to <1/100
Rare≥1/10,000 to <1/1,000
Infections and infestations
Vulvovaginal mycotic infection
Nervous system disorders
Headache
Gastrointestinal disorders
Abdominal pain
Nausea
Reproductive system and breast disorders
Vaginal haemorrhage, vaginal discharge or vaginal discomfort
Skin and subcutaneous tissue disorders
Rash
Investigations
Weight increased
Vascular disorders
Hot flush
Hypertension
Post-marketing experience:
In addition to the above mentioned adverse drug reactions, those presented below have been spontaneously reported for patients being treated with estradiol 10 micrograms vaginal tablets and are considered possibly related to treatment. The frequencies for the below mentioned adverse drug reactions cannot be interpreted because these reactions are reported voluntarily from a population of uncertain size:
• Neoplasms benign and malignant (including cysts and polyps): breast cancer, endometrial cancer
• Immune system disorders: generalised hypersensitivity reactions (e.g. anaphylactic reaction/shock)
• Metabolism and nutrition disorders: fluid retention
• Psychiatric disorders: insomnia
• Nervous system disorders: migraine aggravated
• Vascular disorders: deep vein thrombosis
• Gastrointestinal disorders: diarrhoea
• Skin and subcutaneous tissue disorders: pruritus, rash, urticaria,
• Reproductive system and breast disorders: endometrial hyperplasia, vulvovaginal pain1, pruritus genital
• General disorders and administration site conditions: application site reaction2, drug ineffective, injury associated with device3
1 Including Vulvovaginal burning sensation
2 Local allergic reactions including Vulvovaginal erythema, Genital erythema, Vulvovaginal rash, Genital rash
3 Minor local trauma caused by intravaginal applicator
Other adverse reactions have been reported in association with systemic oestrogen/progestagen treatment. As risk estimates have been drawn from systemic exposure it is not known how these apply to local treatments:
• Gall bladder disease
• Skin and subcutaneous disorders: chloasma, erythema multiforme, erythema nodosum, vascular purpura
• Probable dementia over the age of 65 (see section 4.4).
Class effects associated with systemic HRT
The following risks have been associated with systemic HRT and may apply to a lesser extent for oestrogen products for vaginal application of which the systemic exposure to oestrogen remains within the normal postmenopausal range.
Ovarian cancer
Use of systemic HRT has been associated with a slightly increased risk of having ovarian cancer diagnosed (see section 4.4).
A meta-analysis from 52 epidemiological studies reported an increased risk of ovarian cancer in women currently using systemic HRT compared to women who have never used HRT (RR 1.43, 95% CI 1.31-1.56). For women aged 50 to 54 years who have been taking HRT for 5 years, this results in about 1 extra case per 2,000 users. In women aged 50 to 54 who do not take HRT, about 2 women in 2000 will be diagnosed with ovarian cancer over a 5-year period.
Risk of venous thromboembolism
Systemic HRT is associated with a 1.3- to 3-fold increased relative risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of using HRT (see section 4.4). Results of the WHI studies are presented below:
WHI Studies – Additional risk of VTE over 5 years' use
* Study in women with no uterus.
Risk of ischaemic stroke
The use of systemic HRT is associated with an up to 1.5-fold increased relative risk of ischaemic stroke. The risk of haemorrhagic stroke is not increased during the use of HRT.
This relative risk is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of stroke in women who use HRT will increase with age (see section 4.4).
WHI studies combined – Additional risk of ischaemic stroke* over 5 years' use
Age range (years)
Incidence per 1,000 women in placebo arm over 5 years
Risk ratio and 95% CI
Additional cases per 1,000 HRT users over 5 years
50 – 59
8
1.3 (1.1 – 1.6)
3 (1 – 5)
* No differentiation was made between ischaemic and haemorrhagic stroke.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Gina is intended for intravaginal use and the dose of estradiol is very low. Overdose is therefore unlikely, but if it occurs, treatment is symptomatic.
Ask anything about Gina 10 micrograms vaginal tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.